BACKGROUND & OBJECTIVES The proto-oncogene HER2/neu has been extensively studied in breast cancer patients. Serum levels of HER2/neu by ELISA in breast cancer patients were compared with tissue HER2/neu expression and with other clinicopathological parameters with the aim to investigate whether the serum assay could replace the established tests (IHC/FISH) for HER-2 status. METHODS Blood and ...

The objectives for this study are to find the relationship between; breast cancer with hormone receptors , family history and receptors. A prospective data collected from 251 mastectomies female patients due cancer. analyzed regarding age weight of patient Ca parity site, size tumor receptor status. total 5.57% them young group(20-29years) 21.51% premenopausal group (30-50 years). ER is positiv...

The human epidermal growth factor family of receptors (HER1/EGFR, HER2, HER3, and HER4) plays an important role in the proliferation, differentiation, and transformation of tumor cells (Gianni et al., 2010). The receptors are highly expressed in many solid tumor types, including breast cancer. Approximately 15% to 30% of breast cancers overproduce the growth-promoting protein HER2/neu. These tu...

PURPOSE To evaluate serum levels of HER2 (an epithelial growth factor) and YKL-40 (a growth factor participating in inflammation and remodeling of the extracellular matrix) in relation to outcome in patients with their first diagnosis of recurrent breast cancer. DESIGN Serum HER2 and YKL-40 levels were measured in 100 patients referred with their first metastatic manifestation of breast cance...

INTRODUCTION Mucinous carcinoma is a variant of invasive breast carcinomas that accounts for 2% of them and has a better prognosis in contrast to the non-specific invasive carcinoma. They regularly are positive for estrogen and progesterone receptors and, generally, they do not overexpress HER2. When HER2 is positive, the first line treatment is trastuzumab; although the resistance is 52-89% fo...

Background: Breast carcinoma is the most common malignancy in female worldwide, leading cause of death women. Immunohistochemistry plays a very important role prognostication and treatment determination breast patients. Objective: The objective study was to analyze immunohistochemical markers invasive correlate expression hormonal receptors with age patient, tumor size, histological grade, lymp...

BACKGROUND Assessment of the status of tumor biomarkers in individual patients would facilitate personalizing treatment strategy, and continuous monitoring of those biomarkers and their binding process to the therapeutic drugs would provide a means for early evaluation of the efficacy of therapeutic intervention. Fluorescent probes can accumulate inside the tumor region due to the leakiness of ...

Herein, we describe a versatile immunoassay that uses biotinylated single-walled carbon nanotubes (SWNTs) as a Raman label, avidin-biotin chemistry to link targeting ligands to the label, and confocal Raman microscopy to image whole cells. Using a breast tumor cell model, we demonstrate the usefulness of the method to assess membrane receptor/ligand systems by evaluating a monoclonal antibody, ...

Therapeutics against breast cancer is a major research field, due to inefficiency or partial efficiency of existing therapeutics. An urge discover better therapeutics always persists. Our objective study salicin cells, in order find its therapeutic properties. To the effect on we performed MTT assay MCF-7 (hormone positive) and MDA-MB-231 (triple negative) cell lines, did brine shrimp lethality...

Breast cancer is the leading cause of cancer mortality in females worldwide. Studies based on gene expression profiles have identified different breast cancer molecular subtypes, such as luminal A and B cells, cancer cells that are estrogen receptor (ER) and/or progesterone receptor (PR) positive, human epidermal growth factor 2 (HER2)-enriched cells, cancer cells that exhibit an overexpression...